Is Cullinan Therapeutics, Inc. overvalued or undervalued?

As of 16 May 2022, the valuation grade for Cullinan Therapeutics, Inc. moved from risky to does not qualify, indicating a significant deterioration in its financial standing. The company is currently considered overvalued based on its financial metrics. Key ratios include a Price to Book Value of 0.97, an EV to EBIT of -1.12, and a ROCE of -83.79%.
In comparison to its peers, Cullinan Therapeutics has a notably lower valuation profile, with Procaps Group SA being very attractive at a P/E of 605.22, while ARS Pharmaceuticals, Inc. is classified as risky with a P/E of -92.41. The company's recent stock performance has been poor, with a year-to-date return of -37.77%, contrasting sharply with the S&P 500's positive return of 2.44% during the same period, further reinforcing the view that it is overvalued.